Please login to the form below

Not currently logged in
Email:
Password:

Rubius Therapeutics poaches Novartis’ Spencer Fisk

He joins the US biotech as its senior VP manufacturing

Novartis’ former vice president and global head of cell and gene technical development and manufacturing Spencer Fisk has decided to join Rubius Therapeutics.

He takes up its senior vice president of manufacturing role as the company is looking to expand its manufacturing and development organisations.

Torben Straight Nissen, president of Rubius Therapeutics, said: “Spencer’s expertise and decades of experience in process development and manufacturing will be invaluable and I look forward to working closely together as we continue to deliver on the promise of the next generation of cellular therapies for patients in need.”

Prior to his new role, Fisk spent the last six years at Novartis where he led the CMC development-manufacturing organisation to deliver the CAR-T portfolio of the company.

He has also held a series of leadership positions for both Merck and Schering Plough.

Fish said: “Rubius is developing an entirely new class of ready-to-use cell therapeutics to treat cancer, autoimmune disorders and rare diseases.

“I look forward to leveraging the expertise i've gained while working with larger pharmaceutical companies to help Rubius take its extraordinary RTC pipeline into the clinic.”

6th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics